The United States Patent and Trademark Office (USPTO) has issued patent US12582846B2 for an "Absolute in vivo radiation dosimetry tool with XACT imaging." The patent, assigned to The Regents of the University of California, describes a system using X-ray-induced acoustic computed tomography (XACT) with a model-based reconstruction method to measure the absolute radiation dose delivered to tumors and surrounding tissues during radiotherapy. This technology aims to enhance the precision of cancer treatment by providing real-time, absolute dose information, potentially leading to more personalized treatment plans and improved patient outcomes.

This patent grant represents a new technological development in medical devices for radiation therapy. While not a regulatory rule imposing new compliance obligations, it signifies innovation in the field of oncology treatment monitoring. Healthcare providers and medical device manufacturers involved in radiotherapy should be aware of this patented technology, as it may influence future treatment protocols, device development, and clinical research. The patent details the use of thermal parameters and calibration tools like ion chambers for accurate dose reconstruction, highlighting potential areas for technological advancement and integration into clinical practice.